Discover investment opportunities in Biotechnology Penny Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotechnology Penny Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotechnology Penny Stocks using our Smart AI Filter.
7 stocks found for "Biotechnology Penny Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.13 | ±100.0% | -0.1 | 0.00% | |||
1.55 | ±74.2% | 14.9 | 0.00% | |||
0.70 | ±100.0% | -0.8 | 0.00% | |||
0.76 | ±100.0% | -0.5 | 0.00% | |||
1.39 | ±90.0% | -0.7 | 0.00% | |||
1.14 | ±95.4% | -1.3 | 0.00% | |||
0.65 | ±51.4% | -4.3 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors might influence the volatility of biotechnology penny stocks like ADMA or MNKD?
A: Biotechnology penny stocks such as ADMA and MNKD often exhibit high volatility due to clinical trial outcomes, regulatory decisions, and shifts in investor sentiment. Their reliance on single or few product developments can lead to sharp price movements, particularly surrounding FDA approvals or rejections.
Q: How can investors assess the growth potential of RXRX and other biotechnology companies?
A: Investors may assess growth potential by evaluating the company's pipeline of drugs, stage of clinical trials, R&D spending, and management's expertise. Understanding partnerships or collaborations with larger pharmaceutical firms can provide additional insights into growth opportunities.
Q: Are biotechnology penny stocks like PLXP suitable for income-seeking investors?
A: Generally, biotechnology penny stocks such as PLXP are not ideal for income investors, as they typically do not offer dividends. These companies often reinvest earnings into research and development, seeking long-term capital appreciation rather than short-term income.
Q: What should investors consider about the regulatory risks for companies like VCNX?
A: Investors should consider the potential impact of FDA regulatory decisions and changing healthcare policies on VCNX and similar stocks. Delays or negative outcomes in clinical trials can adversely affect stock prices, so understanding the regulatory environment is crucial.
Q: How might economic cycles affect biotechnology stocks like BDSI?
A: Biotechnology stocks such as BDSI may be less sensitive to economic cycles due to healthcare's necessity. However, funding cutbacks during downturns can impact research activities. Investors should assess how each company manages its financial stability through various economic phases.
Q: Can biotechnology stocks like BIOL provide portfolio diversification benefits?
A: Some investors consider biotechnology stocks like BIOL as a diversification tool due to their unique risk and return profile, which may be less correlated with other sectors. However, high volatility and potential for large price swings must be considered.
Puma Biotech (PBYI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read moreOn Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.
Read moreOn Friday, Galectin Therapeutics, Inc. GALT released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
Read more